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468 | Med. Chem. Commun., 2014, 5,Synthesis and biological evaluation of new
conformationally restricted S-DABO hybrids as
non-nucleoside inhibitors of HIV-1 reverse
transcriptase†
Hai-Qiu Wu,a Christophe Pannecouque,b Zi-Hong Yan,a Wen-Xue Chen,a
Qiu-Qin He,*a Fen-Er Chen,*ac Jan Balzarini,b Dirk Daelemansb and Erik De Clercqb
A series of conformationally restricted dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) hybrids, which
combined the structural features of C6-a-methylbenzyl-thio-DABOs (a-methyl-S-DABOs) and C6-a-
cyanobenzyl-thio-DABOs (CN-S-DABOs), has been synthesized and biologically evaluated for their
anti-HIV activity against wild-type HIV-1 strain IIIB, double RT mutant (K103N + Y181C) strain RES056
and HIV-2 strain ROD in MT-4 cell cultures. Most of these compounds exhibited inhibitory activity
(wild-type) within the range of EC50 values from micromolar to nanomolar. Among them, compound
1s displayed the highest anti-HIV-1 activity with an EC50 value of 91 nM and a selectivity index (SI) of
548, which was more potent than zalcitabine and comparable to nevirapine and delavirdine in the
same assay. The HIV-1 reverse transcriptase inhibitory (RT) assay confirmed that these conformationally
restricted S-DABO hybrids targeted HIV-1 RT. The preliminary structure–activity relationship (SAR) and
molecular docking analysis of this new series of conformationally constrained CN-S-DABO hybrids
were also investigated.Introduction
Non-nucleoside reverse transcriptase inhibitors (NNRTIs),
known as one of the indispensable components of highly active
antiretroviral therapy (HAART), have attracted wide attention
due to their high specicity, excellent potency and low cyto-
toxicity.1–3 With years of efforts, many kinds of NNRTIs
with diverse structures have been developed, such as
dihydroalkoxybenzyloxopyrimidines (DABOs), 1-[(2-hydroxy-
ethoxy)methyl]-6-(phenylthio)thymines (HEPTs), diaryltriazines
(DATAs), and diarylpyrimidines (DAPYs).3–5
Since the rst series of DABOs were disclosed as a novel
class of NNRTIs in 1992,6 many structural modications have
been made and led to the discovery of numerous promising
DABO families such as S-DABOs, N-DABOs, DATONs, DABOCsy, Shanghai 200433, People's Republic of
@fudan.edu.cn; Fax: +86 21 65643811;
euven, 10 Minderbroedersstraat, B-3000
University, Shanghai 200433, People's
(ESI) available: Includes the detailed
ata for all new compounds, materials
and molecular simulation. See DOI:
468–473and a-methyl-DABOs (Fig. 1).4,7,8 Among them, conformation-
ally restricted a-methyl-S-DABOs characterized by a methyl
group at the methylene bridge between the pyrimidine and
phenyl rings exhibited excellent inhibitory potencies against
both wild-type HIV-1 and drug-resistant mutants without
signicant cytotoxicity at higher concentrations.9–18 Upon
analysis of the le wing of a-methyl-S-DABOs, the p-methox-
ybenzyl moiety seems to be the most favorable for the inter-
actions with the entrance of the non-nucleoside inhibitor
binding pocket (NNIBP).14
In our previous DABO project,19 we introduced a CN group at
the methylene bridge and obtained a novel series of potent CN-
S-DABOs. The most active compound 3 (Fig. 2) showed strong
inhibitory potency with an EC50 value of 2 nM. The docking
study revealed that its a-cyanobenzyl moiety tted into the
aromatic-rich NNIBP, surrounded by the aromatic side chains of
Tyr181, Tyr188, Phe227 and Trp229, as well as Leu234 and
Pro95. Considering that the a-CN group at the benzylic position
could enhance p–p stacking interaction with the surrounding
aromatic residues and it could also result in a restricted
conformation as 2, we combined the structural features of 2 and
3 to generate a new series of CN-S-DABO hybrids with the aim to
develop a novel class of conformationally restricted S-DABO
analogs in present work. Herein we report the synthesis and
biological evaluation of these new a-CN-S-DABO hybrids 1
(Fig. 2).This journal is © The Royal Society of Chemistry 2014
Fig. 1 Typical representations of the DABO family.
Fig. 2 The lead compounds and newly designed C6-rigid S-DABOs 1.
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View Article OnlineResults and discussions
Chemistry
The newly designed compounds 1a–u were obtained from
common intermediates 7a–c, which were easily synthesized in
three steps, as depicted in Scheme 1. The 2-thiobarbituric acid
derivatives 5a–c were prepared according to the method of
Koroniak et al.20 by condensation of thiourea with the corre-
sponding diethyl malonates 4a–c using sodium methoxide as
base in methanol under reuxing conditions. Subsequently, 5a–
c were S-alkylated with freshly made 4-methoxybenzyl chlo-
ride,21 producing the corresponding 5-alkyl-2-alkylthio-
barbituric acids 6a–c which were then treated with
p-toluenesulfonyl chloride and K2CO3 in anhydrous DMF to
afford disulfonates 7a–c. These common intermediates were
then reacted with various substituted benzyl cyanide in the
presence of 60% NaH and air in anhydrous DMF to yield 8a–u,
which were hydrolyzed with 30% aqueous sodium hydroxide to
obtain the target compounds 1a–u.This journal is © The Royal Society of Chemistry 2014Biological evaluation
Anti-HIV activity evaluation on cell cultures. The new series
of a-CN-S-DABO hybrids was biologically evaluated for their
anti-HIV activity against wild-type HIV-1 strain IIIB, double RT
mutant (K103N + Y181C) strain RES056 and HIV-2 strain ROD in
MT-4 cell cultures, in parallel with nevirapine (NVP), zidovudine
(AZT), zalcitabine (DDC), efavirenz (EFV) and delavirdine (DLV)
as reference drugs in the test. The results, expressed as EC50
(anti-HIV activity), CC50 (cytotoxicity) and SI (selectivity index,
given by the CC50/EC50 ratio), are summarized in Table 1.
As seen from the results listed in Table 1, most of these CN-S-
DABOs (1a, 1c–d, 1f–j, 1l–q, 1s–u) showed moderate to good
inhibitory activity against wild-type HIV-1 with EC50 values
ranging from 29.08 to 0.09 mM. Among them, compound 1s
displayed the highest potency with an EC50 value of 0.09 mMand
a selectivity index (SI) > 548, which was more potent than DDC
(EC50¼ 0.57 mM, SI¼ 169), comparable to NVP (EC50¼ 0.11 mM,
SI¼ 132) and DLV (EC50¼ 0.11 mM, SI¼ 338), but more selective
than these reference drugs.Med. Chem. Commun., 2014, 5, 468–473 | 469
Scheme 1 Synthesis of compounds 1a–u. Reagents and conditions: (a) thiourea, MeONa, MeOH, reflux, 4–8 h; (b) 4-methoxybenzyl chloride,
NaOH, H2O, 40 C, 4–6 h; (c) TsCl, K2CO3, DMF, rt., 8–12 h; (d) substituted benzyl cyanide, 60% NaH, DMF, 5 C to rt., 12–24 h; (e) NaH, DMF,
air, rt., 12–24 h; (f) 30% NaOH, 6–8 h.
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View Article OnlinePreliminary SAR information can be summarized from the
data in Table 1 as following: (a) variation in substitution at the
C-5 position of the pyrimidine core had inuence on antiviral
potency. Interestingly, the effect of substitution at the C-5Table 1 Anti-HIV-1 activities and cytotoxicity of compounds 1a–u in MT
Compd R1 R2
EC50
b [mM]
WT (IIIB)
K103N
Y181C
1a Me 3-F 29.08  2.85 >172.7
1b Me 4-F >95.17 NDe
1c Me 2-Cl 0.49  0.32 >115.5
1d Me 3-Cl 18.00  2.27 >160.7
1e Me 4-Cl >28.90 ND
1f Me 2-Br 0.42  0.15 >86.65
1g Me 3-Br 16.28  0.55 >155.9
1h Et 2-F 1.66  0.44 >108.7
1i Et 3-F 7.08  1.14 >172.7
1j Et 2-Cl 1.34  0.46 >76.87
1k Et 4-Br >23.87 ND
1l i-Pr 4-F 20.45  10.01 >136.6
1m i-Pr 2-Cl 3.91  0.24 >27.36
1n i-Pr 4-Cl >40.68 >85.18
1o i-Pr 2-Br 4.46  1.33 >26.67
1p i-Pr 3-Br 5.72  1.00 >118.6
1q Me 2,6-diCl 0.19  0.06 >48.80
1r Me 2-F-4-Br >22.52 ND
1s Me 2-F-6-Cl 0.091  0.027 >50.10
1t Me 2,4-diF 20.66  4.07 >156.8
1u Me 3,5-diF 21.31  2.27 >153.5
NVP 0.11  0.07 5.12 
AZT 0.0064  0.0024 0.0063
DDC 0.57  0.14 ND
EFV 0.0089  0.0015 0.51 
DLV 0.11  0.07 >36.19
2 (ref. 14) 0.000025 ND
3 (ref. 19) 0.002  0.0002 ND
a Data represent the mean of at least three separate experiments. b C
cytopathogenicity by 50%. c Compound concentration that decreases th
(WT) ratio. e ND: not determined.
470 | Med. Chem. Commun., 2014, 5, 468–473position was greatly inuenced by the choice of the C-6 benzylic
substituent. Compound 1p (5-iPr, EC50 ¼ 5.72 mM) exhibited
higher potency than that of 1g (5-Me, EC50 ¼ 16.28 mM), with a
bromide atom at the meta position of the C-6 a-cyanobenzyl-4 cellsa
CC50
c [mM] SId
+
HIV-2
9 >172.79 172.79  25.01 6
>95.17 95.17  72.46 1
1 >115.51 115.51  9.14 239
2 >160.72 160.72  18.09 9
>28.89 28.89  1.95 1
>86.65 86.65  12.84 208
1 >155.91 155.91  12.75 10
7 >108.77 108.77  57.32 66
5 >172.75 172.75  19.60 24
>76.87 76.87  40.90 57
>23.87 23.87  0.97 1
7 >136.67 136.67  25.29 7
>27.36 27.36  2.59 7
>85.18 85.18  42.04 #2
>26.67 26.67  2.75 6
6 >118.66 118.66  17.62 21
>48.80 48.80  33.55 252
>22.52 22.52  0.93 1
>50.10 50.10  26.55 548
9 >156.89 156.89  22.38 8
6 >153.56 153.56  14.33 7
5.14 ND >15.02 >132
 0.00003 0.0060  0.0010 >93.56 >14 445
1.61  1.02 >94.70 >169
0.14 ND >6.34 >727
ND >36.19 >338
ND >12.43
ND 10.81  6.56 4600
ompound concentration required to protect MT-4 cells against viral
e uninfected MT-4 cell viability by 50%. d Selectivity index: CC50/EC50
This journal is © The Royal Society of Chemistry 2014
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View Article Onlinering. Similarly, compound 1l (5-iPr, EC50 ¼ 20.45 mM) was more
potent than 1b (5-Me, EC50 > 95.17 mM), with a uoro atom at
the para position. In addition, compound 1i (5-Et, EC50 ¼
7.08 mM) with a uoro atom at the meta position also displayed
higher antiviral activity than that of 1a (5-Me, EC50¼ 29.08 mM).
It seems that a bulky group is favourable for improving inhib-
itory activity when there is a substituent at the meta or para
position of the C-6 a-cyanobenzyl ring, which is consistent with
the previous reported ndings.19 However, for the compounds
with a substituent at the ortho position, the inhibitory activity
decreased in the order: Me (1c) > Et (1j) > iPr (1m). (b) Despite
the substituent at the C-5 position of the pyrimidine core,
introduction of a substituent at the para position of the C-6
a-cyanobenzyl ring is not tolerable. All the compounds (1b, 1e,
1k, 1l, 1n) with a substituent at the para position completely lost
potency against HIV-1 replication, except for 1l. Introduction of
a substituent at the ortho position is favourable, compounds 1c,
1f, 1h and 1o proved to be more potent than the corresponding
meta position substituted compounds 1d, 1g, 1i and 1p,
respectively. In addition, introduction of an additional substit-
uent at the ortho position led to signicant improvement
in inhibitory potency. Compound 1q (2, 6-diCl, EC50 ¼ 0.19 mM)
and 1s (2-F-6-Cl) were more potent than 1c (2-Cl, EC50 ¼
0.49 mM).
HIV-1 RT inhibition assay
To conrm that RT is the biological target of these newly
synthesized a-CN-S-DABO hybrids, four representative
compounds were selected to carry out an HIV-1 RT inhibitory
assay according to themethod described by themanufacturer of
the EnzCheck RT Assay kit (Molecular Probes, Invitrogen);
nevirapine, efavirenz (EFV) and etravirine (TMC-125) were also
tested in the same assay as the reference drugs.
As shown in Table 2, all the tested compounds showed
potent inhibitory activity against HIV-1 RT and were more
potent than NVP. This strongly supports that the synthesized
hybrids in this study act as NNRTIs. Interestingly, these four
compounds have higher inhibitory activity in HIV-1 replication
(Table 1) than in the RT assay. The reason for this phenomenon
might be that those compounds also inhibit DNA-dependent
DNA polymerase activity, which could not be optimally detected
by the RT assay used in this study.
Molecular simulation
To investigate the potential binding mode of the newly
synthesized compounds with HIV-1 RT, molecular simulationTable 2 Anti-HIV-1 RT (WT) activity of representative compoundsa
Compd 1c 1f 1q 1s NVP EFV TMC-125
IC50
b [mM] 0.51 1.55 0.23 0.17 1.78 0.037 0.017
SDc 0.12 0.51 0.05 0.04 0.19 0.019 0.006
a Data represent the mean of two separate experiments. b Compound
concentration required to inhibit HIV-1 RT (WT) activity by 50%.
c Standard deviation.
This journal is © The Royal Society of Chemistry 2014was conducted by using Sybyl Surex-Dock program, and the
crystallographic structure of wild type RT in complex with TNK-
651 (PDB ID: 1RT2) was used due to the high degree of similarity
between TNK-651 and S-DABOs. The most active compound 1s
either on cell cultures or in RT assay was taken as a represen-
tative compound and chosen for docking analysis. The model-
ling method is illustrated in detail in the ESI,† and theoretical
binding mode of 1s in the NNIBP is shown in Fig. 3. To test the
accuracy and reliability of the docking procedure, the reference
compound TNK-651 taken from the crystal complex was docked
into the NNIBP to predict the binding geometries, which
successfully reproduced the experimental geometries well with
an acceptable root-mean-square deviation (RMSD) value of
0.527 A˚ (see Fig. 4).
The docking simulation clearly shows that 1s forms two
hydrogen bonds with the residue Lys101 of HIV-1 RT. One was
observed between the NH of the pyrimidinone ring and the
peptidic carbonyl oxygen of Lys101, another was between the
C]O fragment of the pyrimidinone ring and the NH of Lys101,
with atom-pair distances of 1.81 A˚ and 2.13 A˚, respectively. This
might efficiently stabilize the NHC]O fragment at the N3/C4
positions of the pyrimidinone ring and lower the energy of the
active conformations of 1s in NNIBP. Therefore, these two
hydrogen bonds play an important role in the strong potency of
1s against HIV-1 RT. The methyl group at the C5 position and
the substituted a-cyanobenzyl moiety of 1s at the C6 position
were located in an aromatic rich hydrophobic region dened by
the aromatic side chains of Tyr181, Tyr188, Trp229, as well as
Tyr 232 and Pro95. Notably, the electron-decient 2-F-6-Cl-
benzyl moiety was almost parallel with the electron-rich
benzene ring of Tyr181 residue, which would result in a strongFig. 3 Predicted binding mode of compound 1s and the non-nucle-
oside inhibitor binding pocket (NNIBP) of wild-type HIV-1 RT (PDB
code: 1RT2). Hydrogen bonds are indicated with dashed lines in
yellow.
Med. Chem. Commun., 2014, 5, 468–473 | 471
Fig. 4 Comparison of the docked TNK-651 and X-ray conformation of
TNK-651 into NNIBP.
MedChemComm Concise Article
Pu
bl
ish
ed
 o
n 
09
 Ja
nu
ar
y 
20
14
. D
ow
nl
oa
de
d 
by
 K
U
 L
eu
ve
n 
U
ni
ve
rs
ity
 L
ib
ra
ry
 o
n 
10
/1
1/
20
14
 0
9:
11
:1
1.
 
View Article Onlinep–p stacking interaction. The cyano group linked to the benzyl
ring further enhanced this p–p stacking interaction. Unfortu-
nately, the orientation of the p-methoxybenzyl moiety at the C2
position was not maintained, directing to residues Val179
rather than Asp192, and pushing the residue Val179 and Tyr181
away from Tyr188, which might disrupt the entrance of the
binding pocket and the hydrogen bond network between RT
residues, which played an important role in the excellent
activity of 6a.14Conclusion
In summary, a series of new conformationally restricted S-DABO
hybrids with a substituted a-cyanobenzyl group at C6 of
pyrimidine were synthesized and evaluated in cellular assays.
Most of the target compounds showed inhibitory activity
against wild-type HIV-1 with EC50 values ranging from 40.68 to
0.09 mM. The most potent compound 1s exhibited a low EC50
value of 0.09 mM and SI > 548, and was more potent than the
reference drug DDC and comparable to NVP and DLV, but more
selective. The HIV-1 RT assay conrmed that these newly
synthesized compounds targeted HIV-1 RT. The present bio-
logical and docking studies revealed some important SARs for
this series of S-DABO hybrids: (a) the pyrimidine core is crucial
for maintaining inhibitory potency by forming H-bonds with
Lys101, (b) introduction of electron decient substituent at the
ortho position of the C-6 benzyl ring is helpful for enhancing
affinity of the inhibitors and RT, (c) a small group is favorable
for improving inhibitory potency when substituted at the ortho
position of the C-6 benzyl ring, (d) incorporation of a CN group
at the C-6 benzyl ring can enhance p–p stacking interaction
with Tyr181, Tyr188, Trp229, Tyr232 and Pro95. Further472 | Med. Chem. Commun., 2014, 5, 468–473structural optimization of S-DABOs analogues will take into
account these aspects for developing more active and selective
NNRTIs.Acknowledgements
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